Advanced Emphysema
Conditions
Keywords
emphysema, aeris, PLVR, BLVR, germany, treatment, device, breathing
Brief summary
This is a multi-center, open-label, non-controlled Pilot Study. Approximately 24 patients will be assigned to one of 3 treatment groups (8 patients each group). Patients in each group will receive 2, 4, and 6 (3 followed by a retreatment of 3) subsegmental treatments, respectively. All patients will receive treatment in a single lung under conscious sedation or general anesthesia. Patients will be followed for 24 weeks after completion of PLVR treatment(s). Upon completion of 12-week follow-up, all safety and efficacy data will be analyzed to determine an effective treatment dose. Thereafter, Group 1 patients may elect to be retreated at additional sites so that their total dose received is consistent with the effective dose. All study patients will receive standard medical therapy in addition to PLVR.
Interventions
DEVICEPolymeric Lung Volume Reduction System (PLVR)
20ml (each) of polymer will be injected into 2, 3 or 4 subsegments during the first treatment. Eligible patients may have 20ml (each) of polymer will be injected into 2 or 3 subsegments during the second treatment.
Sponsors
Aeris Therapeutics
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have a diagnosis of advanced upper lobe predominant (ULP) emphysema or advanced disease in the superior lower lobes as defined by FEV1/FVC \<70 % predicted, FEV1 of \< 50% predicted, TLC \> 100% of predicted, and RV \> 135% predicted. * Patients must have persistent symptoms despite medical therapy and either not be candidates for Lung Volume Reduction Surgery (LVRS) or have elected not to undergo LVRS. * Patients must be \> 40 years of age, have symptoms despite medical therapy, and have none of the pre-specified co-morbid conditions that could influence study outcomes or their ability to tolerate bronchoscopy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in the ratio of Residual Volume (RV) to Total Lung Capacity (TLC) | 12 and 24 weeks following treatment | Change from baseline in RV/TLC ratio at 12 and 24 weeks following treatment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Forced Vital Capacity (FVC) | 12 and 24 weeks following treatment | Change from baseline in FVC (post bronchodilator) at 12 and 24 weeks following treatment |
| Change in Diffusing Capacity of the Lung for Carbon Monoxide (DLco) | 12 and 24 weeks following treatment | Change from baseline in DLco at 12 and 24 weeks following treatment |
| Change in Forced Expiratory Volume in 1 Second (FEV1) | 12 and 24 weeks following treatment | o Change from baseline in FEV1 (post bronchodilator) at 12 and 24 weeks following treatment |
| Change in distance walked in six minutes | 12 and 24 weeks following treatment | Change from baseline at 12 and 248 weeks in 6 Minutes Walk Test (6MWT) |
| Change in St. George's Respiratory Questionnaire (SGRQ) domain score | 12 and 24 weeks following treatment | Change from baseline in disease-specific health related quality of life assessment (SGRQ) at 12 and 24 weeks following treatment |
| Change in Medical Research Council Dyspnea (MRCD) score | 12 and 24 weeks following treatment | Change from baseline in MRCD score at 12 and 24 weeks |
Countries
Germany
Outcome results
None listed